Archives
-
MYC2-LBD40/42-CRL3BPM4 Tomato Defense
2026-10-01
The reference study identifies a MYC2–LBD40/42–CRL3BPM4 regulatory module that calibrates tomato resistance to Botrytis cinerea rather than simply switching immunity on or off. Its findings connect transcriptional repression, targeted protein degradation, genetic epistasis, and growth–defense allocation, providing a mechanistic framework for studying inducible plant immunity.
-
Doxycycline in Reliable Cell Viability Workflows
2026-10-01
Learn how Doxycycline (SKU BA1003) can be integrated into reproducible cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers assay design, solvent handling, interpretation, and evidence-based product selection.
-
UK-5099 for Mitochondrial Immunometabolism
2026-09-30
Use UK-5099, also called PF-1005023, to test how mitochondrial pyruvate entry shapes cellular energy balance and immune-cell function. This practical framework combines standardized whole-blood stimulation with orthogonal bioenergetic, cytokine, insulin-secretion, and glucose-regulation readouts.
-
Berberine, RXRα/PPARγ, and SASP in Atherosclerosis
2026-09-30
A 2025 study identifies an RXRα/PPARγ/NEDD4 axis linking berberine treatment to reduced SASP-associated inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of Smart-seq profiling, molecular validation, and macrophage-specific RXRα knockdown provides a useful framework for testing how nuclear receptor signaling controls inflammatory aging.
-
Protease Inhibitor Cocktail for Dual-Genome OXPHOS
2026-09-29
Learn how a Protease Inhibitor Cocktail and EDTA-Free Protease Inhibitor strategy can protect protein-level evidence in LRPPRC–dasatinib OXPHOS studies. This guide connects inhibitor selection with causal interpretation, assay design, and reproducible cancer metabolism workflows.
-
Tetrahydrocurcumin Derivative Shows Anti-CRC Activity
2026-09-29
Chen et al. developed α, β-unsaturated tetrahydrocurcumin derivatives and identified fluorinated compound C5 as a potent colorectal cancer candidate with activity in cell and xenograft models. The study links C5 activity to S-phase arrest, apoptosis-related Bcl-2 family regulation, impaired migration, and suppression of PI3K/AKT/mTOR signaling, while also highlighting the importance of preserving protein phosphorylation states during mechanistic assays.
-
Vitamin C, ROS/NF-κB, and Cochlear Senescence
2026-09-28
A 2024 Molecular Biology Reports study used D-galactose-treated HEI-OC1 cochlear hair cells to examine whether vitamin C can counter cellular senescence through the ROS/NF-κB axis. By including N-acetyl-L-cysteine as a redox-oriented comparator, the work connects reduced oxidative burden with improved viability, lower senescence markers, and less inflammatory signaling, while remaining an in vitro mechanistic study.
-
Primidone in ALS: From RIPK1 to Biomarkers
2026-09-28
Primidone (Mysoline) is being investigated in ALS not only as a drug candidate, but also as a probe of RIPK1-related biology. This article examines what the clinical biomarker findings support, what they do not establish, and how to design more informative follow-up assays.
-
Npt1-Mediated Renal Transport of Faropenem
2026-09-27
A 2000 Xenopus oocyte study identified mouse Npt1 as a transporter of faropenem and provided evidence that it may support the luminal step of renal secretion. The findings connect a phosphate transporter to penem antibiotic disposition, while leaving the transporter’s quantitative contribution in intact kidneys and humans unresolved.
-
Protease Inhibitor Cocktail for Lysosome Research
2026-09-26
Preserve TECPR1, KIF1A, and other protein targets during lysosome-damage studies without introducing EDTA into cation-sensitive workflows. This practical guide shows how to use a 100X inhibitor stock during extraction, choose downstream assays, and troubleshoot common losses in signal or complex recovery.
-
Protease Inhibitor Cocktail for HepaRG Workflows
2026-09-25
Fast-differentiated HepaRG cells can make hepatitis D virus experiments more accessible, but protein readouts still depend on careful sample handling. Learn where an EDTA-free Protease Inhibitor Cocktail fits—from cold lysis for immunoblotting to cation-sensitive assays—and where its role ends.
-
APOL1 Evolution, Isoforms, and APOL3 Interactions
2026-09-25
Khalaila and Skorecki integrate APOL1 haplotype analysis, splice-isoform biology, and APOL3 interaction findings to frame new routes for investigating variant-associated cellular injury. Their work strengthens the case for studying APOL1 variants in their genetic and isoform contexts, while leaving the mechanism of kidney injury an open question.
-
Protease Inhibitor Cocktail EDTA-Free: K1010
2026-09-24
Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation. Use it in workflows that need protease control while retaining divalent cations; it is not a substitute for phosphatase inhibitors or a complete assay buffer.
-
Lipo3K Transfection Reagent for Resistance Research
2026-09-24
Use Lipo3K Transfection Reagent to test how candidate genes contribute to paclitaxel resistance, from single-gene knockdown to DNA and siRNA co-transfection. A practical workflow connects the reference study’s cholesterol–transporter findings to tractable cell-based experiments, while separating proposed assay design from the paper’s reported results.
-
Bifendate (DDB): Reliable Assay Design
2026-09-23
A practical, evidence-led guide to using Bifendate (DDB), SKU BA1823, in cell viability, cytotoxicity, autophagy, and lipid-metabolism studies. It covers solvent compatibility, starting exposure conditions, interpretation limits, and how to assess supplier options without overstating the evidence.